A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo

Molecular Cell

Volumn 2, Issue 5, 1998, Pages 617-627

  Kuwabara, Tomoko ^a,b,d   Warashina, Masaki ^a,b,d   Tanabe, Tsuyoshi ^c   Tani, Kenzaburo ^c   Asano, Shigetaka ^c   Taira, Kazunari ^a,b,d  

^a NATL INST FOR ADV INTERDISC RES   (Japan)

^b NATL INST BIOSCI HUM TECHNOL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, MOUSE; CASPASE; CASPASE 3; ENZYME PRECURSOR; INTERLEUKIN 3; MAGNESIUM; MESSENGER RNA; RIBOZYME; VALINE TRANSFER RNA;

ALLOSTERISM; ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL LINE; CHRONIC MYELOID LEUKEMIA; CONFORMATION; CYTOPLASM; DIMERIZATION; DRUG EFFECT; ENZYME SPECIFICITY; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; PHILADELPHIA 1 CHROMOSOME;

ALLOSTERIC REGULATION; ANIMALS; APOPTOSIS; BASE SEQUENCE; CASPASE 3; CASPASES; CELL LINE; CELL LINE, TRANSFORMED; CYTOPLASM; DIMERIZATION; ENZYME PRECURSORS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; HUMANS; INTERLEUKIN-3; LEUKEMIA, MYELOID, CHRONIC; MAGNESIUM; MICE; NUCLEIC ACID CONFORMATION; PHILADELPHIA CHROMOSOME; RNA, CATALYTIC; RNA, MESSENGER; RNA, TRANSFER, VAL; SUBSTRATE SPECIFICITY; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032214088     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(00)80160-4     Document Type: Article

References (43)

1. Amontov, S., and Taira, K. (1996). Hammerhead minizymes with high cleavage activity: a dimeric structure as the active conformation of minizymes. J. Am. Chem. Soc. 118, 1624-1628.
2. Bedi, A., Barber, J.P., Bedi, G.C., el-Deiry, W.S., Sidransky, D., Vala, M.S., Akhtar, A.J., Hilton, J., and Jones, R.J. (1995). BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86, 1148-1153.
3. Bertrand, E., Castanotto, D., Zhou, C., Carbonnelle, C., Lee, G.P., Chatterjee, S., Grange, T., Pictet, R., Kohn, D., Engelke, D., and Rossi, J.J. (1997). The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA 3, 75-88.
4. Birikh, K.R., Heaton, P.A., and Eckstein, F. (1997). The hammerhead ribozyme-structure, function and application. Eur. J. Biochem. 245, 1-16.
5. Choo, Y., Sánchez-García, I., and Klug, A. (1994). In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature 372, 642-645.
6. Dahm, S.C., Derrick, W.B., and Uhlenbeck, O.C. (1993). Role of divalent metal ions in the hammerhead RNA cleavage reaction. Biochemistry 30, 9464-9469.
7. bcr/abl protein. Proc. Natl. Acad. Sci. USA 85, 9312-9316.
8. Dubrez, L., Eymin, B., Sordet, O., Droin, N., Turhan, A.G., and Solary, E. (1998). BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 7, 2415-2422.
9. Eckstein, F., and Lilley, D.M.J. (eds.) (1996). Catalytic RNA, Nucleic Acids and Molecular Biology, Vol. 10. (Berlin: Springer-Verlag).
10. Enari, M., Talanian, R.V., Wong, W.W., and Nagata, S. (1996). Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 380, 723-726.
11. Haseloff, J., and Gerlach, W.L. (1988). Simple RNA enzymes with new and highly specific endonuclease activities. Nature 334, 585-591.
12. Hertel, K.J., Herschlag, D., and Uhlenbeck, O.C. (1996). Specificity of hammerhead ribozyme cleavage. EMBO J. 15, 3751-3757.
13. Huang, Y., and Carmichael, G.G. (1996). Role of polyadenylation in nucleocytoplasmic transport of mRNA. Mol. Cell. Biol. 16, 1534-1542.
14. James, H., Mills, K., and Gibson, I. (1996). Investigating and improving the specificity of ribozymes directed against the bcr-ab/translocation. Leukemia 10, 1054-1064.
15. Kawasaki, H., Ohkawa, J., Tanishige, N., Yoshinari, K., Murata, T., Yokoyama, K.K., and Taira, K. (1996). Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase. Nucleic Acids Res. 24, 3010-3016.
16. Kawasaki, H., Eckner, R., Yao, T.-P., Taira, K., Chiu, R., Livingston, D.M., and Yokoyama, K.K. (1998). Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature 393, 284-289.
17. Kitamura, T., Onishi, M., Kinoshita, S., Shibuya, A., Miyajima, A., and Nolan, G.P. (1995). Efficient screening of retroviral cDNA expression libraries. Proc. Natl. Acad. Sci. USA 92, 9146-9150.
18. Koseki, S., Ohkawa, J., Yamamoto, R., Takebe, Y., and Taira, K. (1998). A simple assay system for examination of the inhibitory potential in vivo of decoy RNAs, ribozymes and other drugs by measuring the Tat-mediated transcription of a fusion gene composed of the long terminal repeat of HIV-1 and a gene for luciferase. J. Control. Release 53, 159-173.
19. Kuwabara, T., Amontov, S., Warashina, M., Ohkawa, J., and Taira, K. (1996). Characterization of several kinds of dimer minizyme: simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes. Nucleic Acids Res. 24, 2302-2310.
20. Kuwabara, T., Warashina, M., Tanabe, T., Tani, K., Asano, S., and Taira, K. (1997). Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. Nucleic Acids Res. 25, 3074-3082.
21. Val-driven short ribozymes. Nature Biotechnol. 16, 961-965.
22. Kuwabara, T., Warashina, M., Nakayama, A., Hamada, M., Amontov, S., Takasuka, Y., Komeiji, Y., and Taira, K. (1998b). Comparison of the specificities and catalytic activities of conventional hammerhead ribozymes, Joyce's DNA enzymes, and novel dimeric minizymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. Gene Ther. Mol. Biol. 1, 435-449.
23. Maekawa, T., Kimura, S., Hirakawa, K., Murakami, A., Zon, G., and Abe, T. (1995). Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by BCR-ABL anti-sense oligonucleoside phosphorothioates. Int. J. Cancer 62, 63-69.
24. McCall, M.J., Hendry, P., and Jennings, P.A. (1992). Minimal sequence requirements for ribozyme activity. Proc. Natl. Acad. Sci. USA 89, 5710-5714.
25. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K.M., Green, D.R., and Cotter, T.G. (1994). BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83, 1179-1187.
26. Muller, A.J., Young, J.C., Pendergast, A.M., Pondel, M., Landau, N.R., Littman, D.R., and Witte, O.N. (1991). BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol. Cell. Biol. 11, 1785-1792.
27. Nagata, S. (1997). Apoptosis by death factor. Cell 88, 355-365.
28. Nowell, P.C., and Hungerford, D.A. (1960). A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497-1499.
29. Pachuk, C.J., Yoon, K., Moelling, K., and Coney, L.R. (1994). Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequence. Nucleic Acids Res. 22, 301-307.
30. Pendergast, A.M., Gishizky, M.L., Havlik, M.H., and Witte, O.N. (1993). SH1 domain autophosphorylation of p210 BCR/ABL is required for transformation but not growth factor independence. Mol. Cell. Biol. 13, 1728-1736.
31. Perriman, R., and de Feyter, R. (1997). tRNA-delivery systems for ribozymes. In Methods in Molecular Biology, Ribozyme Protocols, P.C. Turner, ed. (Totowa, NJ: Humana Press), pp. 393-402.
32. Porta, H., and Lizardi, P.M. (1995). An allosteric hammerhead ribozyme. Biotechnology 13, 161-164.
33. Reuther, J.Y., Reuther, G.W., Cortez, D., Pendergast, A.M., and Baldwin, Jr., A.S. (1998). A requirement for NF-kB activation in Bcr-Abl-mediated transformation. Genes Dev. 12, 968-981.
34. Smetsers, T.F., Linders, E.H., van de Locht, L.T., de Witte, T.M., and Mensink, E.J. (1997). An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukemia patient cells by a non-antisense mechanism. Br. J. Hematol. 96, 377-381.
35. Steitz, T.A., and Steitz, J.A. (1993). A general two-metal-ion mechanism for catalytic RNA. Proc. Natl. Acad. Sci. USA 90, 6498-6502.
36. Sullenger, B.A., and Cech, T.R. (1993). Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262, 1566-1569.
37. Symons, R.H. (1989). Self-cleavage of RNA in the replication of small pathogens of plants and animals. Trends Biochem. Sci. 14, 445-450.
38. Tang, J., and Breaker, R.R. (1997a). Rational design of allosteric ribozymes. Chem. Biol. 4, 453-459.
39. Tang, J., and Breaker, R.R. (1997b). Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection. RNA 3, 914-925.
40. Uhlenbeck, O.C. (1987). A small catalytic oligonucleotide. Nature 328, 596-600.
41. Yu, M., Leavitt, M.C., Maruyama, M., Yamada, O., Young, D., Ho, A.D., and Wong-Staal, F. (1995). Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 92, 699-703.
42. Vaerman, J.L., Lammineur, C., Moureau, P., Lewalle, P., Deldime, F., Blumenfeld, M., and Martiat, P. (1995). BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 86, 3891-3896.
43. Zhou, D.-M., and Taira, K. (1998). The hydrolysis of RNA: from theoretical calculations to the hammerhead ribozyme-mediated cleavage of RNA. Chem. Rev. 98, 991-1026.